United Therapeutics News

The firm currently has a $51.00 target price on the stock. Zacks ' analyst wrote, "United Therapeutics' first quarter earnings of $1.29 per share were well above the year-ago earnings of $0.31 and the Zacks Consensus Estimate of $0.93. Higher revenues and lower costs led to the improvement in earnings.

The firm currently has a "buy" rating on the stock. The analysts wrote, "UTHR reported revenues of $110.5 million, $70.1 million and $22.3 million for Remodulin, Tyvaso and Adcirca for 1Q12 which was essentially inline with consensus estimates.

CHICAGO, April 27, 2012 /PRNewswire/ -- Today, Zacks Equity Research discusses the Pharmaceuticals & Biotech Industry, including Eli Lilly , Forest Labs , ViroPharma , Novartis and United Therapeutics .

Shares of United Therapeutics opened at 44.54 on Friday. United Therapeutics has a one year low of $36.55 and a one year high of $69.01. The company has a market cap of $2.389 billion and a P/E ratio of 12.13. The company last announced its quarterly results on Thursday, April 26th.

Lockheed Martin of Bethesda reported that its first-quarter profit grew to $668 million from $530 million in the prior-year quarter.